144
edits
(Created page with "There is controversy whether short QT intervals are associated with sudden death. One trial found QTc intervals < 300ms to be associated with sudden death.<cite>Gaita</cite> Howe...") |
No edit summary |
||
Line 1: | Line 1: | ||
<i>Auteur: Louise R.A. Olde Nordkamp</i> | |||
[[ | <i>Supervisor: Arthur A.M. Wilde</i> | ||
The '''short QT syndrome''' is a very rare syndrome characterized by an abnormally short QT interval and increased risk of ventricular fibrillation and cardiac death. | |||
==Clinical diagnosis== | |||
[[Image:ShortQT_syndrome_patient.png|thumb|right]] | |||
The diagnosis is based on the presence a short QT interval, in which the upper limit is mostly set on 330 ms. Males are more often affected than women. A history of cardiac arrest is present in one-third. Patients are at risk for both atrial arrhythmias (AF) and ventricular arrhythmias (VT/VF). | |||
==Physical examination== | |||
Patients can present with symptoms of arrhythmias: | |||
*Out-of-hospital-cardiac-arrest | |||
*Syncope, pre-syncope (weakness, lightheadedness, dizziness) | |||
==ECG tests== | |||
[[Image:Bazett.png|thumb|left]] | |||
The ECG demonstrates a corrected QT interval significantly below the limit of normal (<330 ms). Additionally, notable ECG findings are the presence of a sharp T-wave beginning at the end of the QRS complex, preceded by a brief or absent ST-segment. Exercise electrocardiographic studies in SQTS patients also characteristically reveal a non-physiologic lack of QT shortening at increased heart rates. | |||
==Genetic diagnosis== | |||
[[Image:ShortQT_syndrome_mechanism.png|thumb|left]] | |||
In a quarter of the patients a mutation is found, predominantly in the KCNH2 gene (SQTS1). This gain-of-function mutation causes an increase in the potassium efflux and, subsequently, to a decrease of the myocyte refractory period. Mutations in the KCNQ1, KCNJ2 and possibly CACNxxx genes are also associated with the SQTS. | |||
==Risk Stratification== | |||
Risk stratification in SQTS is still ill-defined and should be done by a specialized cardio-genetic cardiologist. | |||
==Treatment== | |||
Hydroquinidine is suggested for normalization of the QT interval in patients with a KCNH2 mutation. ICD therapy is advised in SQTS patients for secondary prevention of sudden cardiac death and could be considered | |||
== References == | == References == | ||
<biblio> | <biblio> | ||
# | #Giustetto pmid=16926178 | ||
#Giustetto2 pmid=21798421 | |||
# | #Patel pmid=20716721 | ||
# | |||
</biblio> | </biblio> |